New Delhi, Nov. 10 -- Danish drugmaker Novo Nordisk on Monday announced an exclusive partnership with Pune-based Emcure Pharmaceuticals to widely distribute its weight-loss therapy semaglutide, as competition in India's fast-growing anti-obesity drug market heats up.

The announcement comes soon after US drug giant Eli Lilly announced a similar tie-up last month with Mumbai-headquartered Cipla to distribute its anti-obesity drug Tirzepatide.

Novo and Emcure will launch semaglutide under a new brand name, Poviztra, as a 2.4mg weekly injection, they said in a joint statement. The companies did not yet reveal the pricing strategy and launch date, but said that they would be "very competitive" in pricing.

Novo Nordisk currently markets sema...